Ken Brameld

Ken Brameld, Ph.D., is our Fellow, Head of Research. Before joining Alumis, he was senior vice president and Head of Research at Principia Biopharma. At Principia Biopharma, Ken was instrumental in launching the company in 2011 and helped build the Tailored Covalency platform central to the company’s success. During his tenure, the small molecule drug discovery team discovered and progressed four molecules into clinical development, including rilzabrutinib and tolebrutinib. Prior to Principia Biopharma, Ken spent four years at Roche Palo Alto, where he was a Principal Scientist and the Computational Chemistry group leader until the site closure in 2010. Ken began his biotech career with positions of increasing responsibility at Scios, Array Biopharma, and Celera. He earned his Ph.D. in Chemistry from Caltech under the supervision of Prof. William Goddard, III and went on to a postdoctoral fellowship at UCSF in the laboratory of Prof. Irwin “Tack” Kuntz.